Fierce Biotech: Making 'cold' tumors responsive to immunotherapy
UC research points to combination therapy involving the immune system for breast cancer
Some cancers create a hostile environment that allows them to evade immune attacks. That's why many patients with cancer don't respond to immuno-oncology treatments. Scientists are looking for ways to turn these so-called “cold” tumors into “hot” ones that are susceptible to immunotherapy.
A research study by scientists at the University of Cincinnati have discovered proteins that can be targeted to overcome resistance to cancer immunotherapy in animal models.
Syn Kok Yeo, PhD, research instructor in the department of cancer biology at the UC College of Medicine and a member in the lab of Jun-Lin Guan, PhD, the Francis Brunning Professor and Cancer Biology Department Chair, describes his research. He is a member of the UC Cancer Center.
Featured photo of stress fibers and microtubules in human breast cancer cells. Courtesy of the National Cancer Institute.
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
Does the president's prescription drug site actually make medications affordable?
March 20, 2026
Local 12 turned to Erwin Erhardt, PhD, economics professor in UC’s Lindner College of Business for insights on direct-to-consumer drugs.
What is a business venture?
March 20, 2026
Business ventures are ambitious pursuits in which entrepreneurs take on risk to create products and services that solve real customer problems.
Fusion reactors may be key to uncovering dark matter
March 20, 2026
Popular Mechanics highlights a new study by University of Cincinnati physicist Jure Zupan that explains how fusion reactors might create subatomic particles associated with dark matter.